Tuberculosis

1. Introduction

Tuberculosis (TB) is a communicable infectious disease caused predominantly by bacteria of the Mycobacterium tuberculosis complex. It represents a major global public health challenge, ranking among the leading causes of death from a single infectious agent. The disease typically affects the lungs (pulmonary TB) but can disseminate to virtually any organ system (extrapulmonary TB). The management of TB is a cornerstone of infectious disease pharmacology, requiring a nuanced understanding of bactericidal and sterilizing drug activity, prolonged combination chemotherapy, and the management of complex drug interactions and adverse effects.

1.1. Historical Background

The history of tuberculosis is deeply intertwined with medical and therapeutic evolution. Evidence of spinal TB has been identified in Egyptian mummies. Historically termed “consumption” or the “white plague,” its infectious nature was established by Jean-Antoine Villemin in 1865 and the causative bacillus identified by Robert Koch in 1882. The pre-antibiotic era relied on sanatorium care. The modern chemotherapeutic era began with the discovery of streptomycin in 1943, followed by para-aminosalicylic acid and isoniazid, which enabled effective combination therapy and dramatically reduced mortality in high-income countries.

1.2. Importance in Pharmacology and Medicine

The pharmacology of anti-tuberculosis agents presents unique challenges that are fundamental to medical and pharmaceutical education. These include the necessity for multi-drug regimens to prevent resistance, the prolonged duration of treatment required to eradicate dormant bacilli, the significant potential for drug-drug interactions (particularly with cytochrome P450 enzyme inducers), and a distinct profile of adverse drug reactions. The emergence and spread of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB have further elevated the importance of rational pharmacotherapy and stewardship.

1.3. Learning Objectives

• Describe the etiology, pathogenesis, and clinical spectrum of Mycobacterium tuberculosis infection, differentiating between latent TB infection (LTBI) and active TB disease.
• Explain the pharmacological principles, mechanisms of action, pharmacokinetics, major adverse effects, and key drug interactions of first-line and second-line anti-tuberculosis agents.
• Outline the standard treatment regimens for drug-susceptible pulmonary TB, including the intensive and continuation phases, and the principles underlying their design.
• Define drug-resistant TB (DR-TB), including MDR-TB and XDR-TB, and summarize the core principles and novel agents used in their management.
• Discuss the pharmacotherapeutic approaches to latent TB infection and special populations, including patients with HIV co-infection, hepatic or renal impairment, and pregnant women.

2. Fundamental Principles

The effective management of tuberculosis is built upon several foundational microbiological, immunological, and pharmacological principles.

2.1. Core Concepts and Definitions

Latent TB Infection (LTBI): A state of persistent immune response to stimulation by M. tuberculosis antigens without evidence of clinically manifest active TB. Individuals with LTBI are asymptomatic, non-infectious, and usually have a positive tuberculin skin test (TST) or interferon-gamma release assay (IGRA), but no radiographic or microbiological evidence of disease. The lifetime risk of progression to active disease is approximately 5–10%, with higher risk in immunocompromised individuals.

Active TB Disease: A clinically symptomatic, typically infectious state characterized by evidence of viable M. tuberculosis organisms, confirmed by microbiological culture or molecular tests, and often supported by compatible clinical and radiographic findings.

Bactericidal Activity: The ability of a drug to kill rapidly dividing mycobacteria, thereby reducing the bacterial load quickly and decreasing infectiousness. Isoniazid is a potent early bactericidal agent.

Sterilizing Activity: The ability of a drug to kill semi-dormant or persisting mycobacteria within macrophages and caseous lesions, which is crucial for preventing relapse. Rifampicin and pyrazinamide are key sterilizing drugs.

Drug Resistance:

• Monoresistance: Resistance to one first-line anti-TB drug.
• Multidrug-Resistant TB (MDR-TB): Resistance to at least both isoniazid and rifampicin.
• Pre-Extensively Drug-Resistant TB (pre-XDR-TB): MDR-TB with additional resistance to any fluoroquinolone.
• Extensively Drug-Resistant TB (XDR-TB): MDR-TB with additional resistance to any fluoroquinolone and at least one of the Group A drugs (bedaquiline, linezolid).

2.2. Theoretical Foundations

The rationale for combination chemotherapy in TB is derived from the classic bacterial population dynamics model proposed by Wallace Fox and others. Within a large population of M. tuberculosis bacilli in a cavitary lesion, naturally occurring random mutations conferring resistance to a single drug exist at a predictable frequency (approximately 10^-6 for isoniazid or streptomycin, 10^-8 for rifampicin). Treatment with a single drug would selectively kill susceptible bacilli, allowing the pre-existing resistant mutants to proliferate, leading to treatment failure. The probability of a bacillus being spontaneously resistant to two unrelated drugs is the product of their individual mutation frequencies (e.g., 10^-6 × 10^-8 = 10^-14), a number far lower than the total bacillary load in advanced disease (~10⁹ bacilli). Therefore, treatment with at least two drugs to which the organism is susceptible prevents the selection of resistant mutants.

2.3. Key Terminology

• Directly Observed Therapy (DOT): A treatment strategy where a healthcare worker or trained observer watches the patient swallow each dose of medication to ensure adherence.
• Intensive (Bactericidal) Phase: The initial phase of treatment, usually 2 months, designed to rapidly kill dividing bacilli, reduce the bacterial population, and render the patient non-infectious.
• Continuation (Sterilizing) Phase: The subsequent phase of treatment, typically 4 months or longer, aimed at eliminating persistent, semi-dormant bacilli to achieve durable cure and prevent relapse.
• Acid-Fast Bacilli (AFB): A characteristic of mycobacteria, due to their lipid-rich cell wall, that allows them to retain certain stains (e.g., Ziehl-Neelsen) despite acid-alcohol decolorization.
• Caseous Necrosis: A form of tissue necrosis characteristic of TB lesions, with a cheese-like appearance, which provides a microenvironment for bacillary persistence.

3. Detailed Explanation

3.1. Etiology and Pathogenesis

Mycobacterium tuberculosis is a slow-growing, aerobic, non-motile rod. Its complex, lipid-rich cell wall, containing mycolic acids, is responsible for acid-fastness, environmental resilience, and resistance to many common antibiotics. Transmission occurs via inhalation of aerosolized droplet nuclei (1–5 µm in diameter) generated when a person with pulmonary or laryngeal TB coughs, sneezes, or speaks. Upon inhalation, bacilli reach the alveolar spaces where they are phagocytosed by alveolar macrophages. The ability of M. tuberculosis to survive and replicate within macrophages by inhibiting phagosome-lysosome fusion is a key virulence factor.

The subsequent host immune response leads to the formation of a granuloma, an organized aggregate of macrophages (often as epithelioid cells and multinucleated giant cells), surrounded by lymphocytes. The granuloma walls off the infection but can also provide a niche for bacterial persistence. Bacilli may remain dormant for years (latent infection). Progression to active disease may occur due to failure of immune containment, resulting in granuloma caseation, liquefaction, and eventual cavitation, which facilitates high bacterial loads and transmission.

3.2. Pharmacology of First-Line Anti-Tuberculosis Drugs

The cornerstone of drug-susceptible TB treatment is a regimen of four first-line drugs: Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), and Ethambutol (E).

3.3. Treatment Regimens for Drug-Susceptible Tuberculosis

The standard of care for newly diagnosed, drug-susceptible pulmonary TB is a 6-month regimen divided into two phases.

Intensive Phase (2 months): HRZE. The four-drug combination achieves rapid bacillary killing, reduces the bacterial population by several logs, and minimizes the probability of selecting drug-resistant mutants. Sputum smear conversion (from positive to negative) typically occurs by the end of this phase.

Continuation Phase (4 months): HR. The two-drug combination eradicates the remaining, slower-replicating, or dormant “persister” bacilli to prevent relapse. The total duration of rifampicin administration is critical for sterilizing efficacy.

This regimen is denoted as 2HRZE/4HR. Treatment duration may be extended for severe disease, delayed response, or certain forms of extrapulmonary TB (e.g., TB meningitis, bone and joint TB). Fixed-dose combinations (FDCs), which combine two or more drugs in a single tablet, are preferred to simplify administration, improve adherence, and prevent monotherapy (e.g., accidentally taking only one drug from separate pills).

3.4. Factors Affecting Treatment and Pharmacokinetics

Several factors can influence the pharmacokinetics and pharmacodynamics of anti-TB drugs, potentially leading to subtherapeutic drug levels and poor outcomes.

4. Clinical Significance

4.1. Relevance to Drug Therapy and Monitoring

The management of TB extends beyond simply prescribing a regimen. Therapeutic drug monitoring (TDM), though not routinely required for all patients, may be critical in cases of treatment failure, relapse, suspected malabsorption, drug-drug interactions, or comorbidities. TDM involves measuring serum drug concentrations (typically at 2 hours post-dose for peak concentration, C_max) to ensure they fall within the expected therapeutic range. Subtherapeutic levels are a risk factor for acquired drug resistance.

Routine clinical and laboratory monitoring is essential. Baseline evaluation typically includes liver function tests (LFTs), serum creatinine, visual acuity testing (if ethambutol is used), and HIV testing. Patients should be monitored monthly for symptoms of hepatotoxicity (nausea, vomiting, jaundice, abdominal pain) and LFTs should be checked if symptoms occur or if there is pre-existing liver disease. Adherence support, often through DOT, is a critical component of successful therapy, reducing the risk of treatment failure, relapse, and drug resistance.

4.2. Management of Adverse Drug Reactions

The management of adverse effects is a frequent clinical challenge. Algorithms exist for managing hepatotoxicity. For asymptomatic elevation of transaminases less than 5 times the upper limit of normal (ULN), treatment may continue with close monitoring. For elevations ≥5x ULN, or ≥3x ULN with symptoms, or any elevation of bilirubin, all potentially hepatotoxic drugs (H, R, Z) should be stopped immediately. After liver function normalizes, drugs are reintroduced sequentially, one at a time, to identify the culprit. Other common reactions, like rifampicin-induced thrombocytopenia or ethambutol-induced optic neuritis, require permanent discontinuation of the offending agent and substitution with an alternative drug.

4.3. Treatment of Latent TB Infection (LTBI)

Treating LTBI is a key public health strategy to prevent progression to active disease. The decision to treat is based on an individual’s risk of progression. Common regimens include:

• Isoniazid Monotherapy: 6–9 months of daily isoniazid, often with pyridoxine. Effective but lengthy.
• Rifampicin Monotherapy: 4 months of daily rifampicin. An alternative, shorter option.
• Isoniazid plus Rifapentine: 3 months of once-weekly therapy under direct observation. This short-course regimen has high completion rates.

The choice of regimen considers drug susceptibility of the likely source case, drug interactions, and patient preferences.

5. Clinical Applications and Examples

5.1. Case Scenario 1: Drug-Susceptible Pulmonary TB

A 45-year-old man presents with a 6-week history of productive cough, night sweats, weight loss, and fever. Chest X-ray reveals a right upper lobe cavitary lesion. Sputum smear is positive for acid-fast bacilli, and molecular testing (Xpert MTB/RIF) confirms M. tuberculosis complex and detects no rifampicin resistance. He is HIV-negative and has no significant past medical history.

Problem-Solving Approach:

1. Diagnosis: The presentation and confirmatory tests establish a diagnosis of smear-positive, pulmonary, drug-susceptible TB.
2. Regimen Selection: Standard first-line therapy is initiated: 2 months of HRZE (Intensive Phase) followed by 4 months of HR (Continuation Phase). A fixed-dose combination tablet is prescribed to simplify therapy.
3. Adherence and Monitoring: The importance of adherence is stressed. DOT is recommended. Baseline LFTs and visual acuity are checked. The patient is counseled on taking medication on an empty stomach and to report any symptoms of hepatitis, visual changes, or persistent nausea.
4. Public Health Measures: The case is reported to public health authorities for contact investigation. The patient is instructed on respiratory isolation until he is non-infectious (typically after 2–3 weeks of effective treatment and clinical improvement).
5. Assessment of Response: Sputum is collected for smear and culture at monthly intervals. Sputum smear conversion (to negative) is expected by the end of the second month. Treatment is completed over 6 months with resolution of symptoms and radiographic improvement.

5.2. Case Scenario 2: Multidrug-Resistant TB (MDR-TB)

A 32-year-old woman with a prior, partially treated episode of TB 5 years ago presents with recurrent cough and fever. Sputum culture grows M. tuberculosis that is resistant to isoniazid and rifampicin (MDR-TB), but susceptible to fluoroquinolones, aminoglycosides, and other second-line drugs.

Problem-Solving Approach:

1. Confirm Diagnosis and DST: Rapid molecular DST (e.g., Xpert MTB/XDR, line probe assays) and phenotypic culture-based DST are essential to guide regimen design. The resistance profile defines it as MDR-TB.
2. Regimen Design: A longer, more complex regimen is required, typically lasting 18–20 months. A standard all-oral regimen for MDR-TB might be constructed as follows, guided by WHO grouping:
   • Group A (Fluoroquinolones): Levofloxacin.
   • Group B (Second-line injectables): Avoided if possible due to toxicity; if used, amikacin for an intensive phase.
   • Group C (Other core agents): Bedaquiline (for 6 months), Linezolid, Clofazimine, Cycloserine.

   Pyrazinamide is often used if susceptibility is unknown or likely, given its unique sterilizing action in acidic environments.

3. Pharmacological Challenges: The regimen involves multiple drugs with severe potential adverse effects: QT prolongation (bedaquiline, fluoroquinolones), peripheral and optic neuropathy (linezolid, ethambutol), psychiatric effects (cycloserine), and hearing loss/renal toxicity (aminoglycosides). Intensive monitoring (ECG, electrolytes, renal function, audiometry, psychiatric review) is mandatory.
4. Adherence Support: DOT is crucial throughout the prolonged treatment. Social and psychological support is often needed.

5.3. Application to Special Populations: TB in Pregnancy

Active TB in pregnancy must be treated promptly due to risks to both mother and fetus. Most first-line drugs are considered relatively safe. Isoniazid, rifampicin, and ethambutol cross the placenta but have not been associated with a consistent pattern of birth defects. Pyrazinamide is also widely used, though its safety profile is less robustly documented; WHO recommends its inclusion in pregnancy regimens. Streptomycin and other aminoglycosides are contraindicated due to risk of congenital deafness. Treatment for LTBI in pregnancy is generally deferred until after delivery unless the woman is at very high risk of progression (e.g., recent infection, HIV co-infection). Pyridoxine supplementation is especially important in pregnant women taking isoniazid.

6. Summary and Key Points

• Tuberculosis is caused by Mycobacterium tuberculosis and manifests as latent infection (LTBI) or active disease. Active pulmonary TB is a major source of transmission.
• Combination chemotherapy is mandatory to prevent the selection of drug-resistant mutants. The probability of spontaneous resistance to two drugs is the product of their individual mutation frequencies.
• First-line therapy for drug-susceptible TB consists of a 2-month intensive phase with Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), and Ethambutol (E), followed by a 4-month continuation phase with H and R (2HRZE/4HR).
• Key pharmacological principles include understanding bactericidal vs. sterilizing activity, the unique role of pyrazinamide in acidic environments, and the potent cytochrome P450 enzyme induction by rifampicin, which drives numerous clinically significant drug interactions.
• Major adverse effects requiring vigilance include hepatotoxicity (H, R, Z), peripheral neuropathy (H), optic neuritis (E), hyperuricemia (Z, E), and orange bodily fluids (R).
• Drug-resistant TB (MDR/XDR-TB) requires prolonged (≥18 months), individualized regimens based on drug susceptibility testing, utilizing second-line agents like fluoroquinolones, bedaquiline, linezolid, and clofazimine, with close monitoring for toxicity.
• Treatment of Latent TB Infection (LTBI) with isoniazid, rifampicin, or isoniazid/rifapentine is a critical preventive strategy for high-risk individuals.
• Special considerations are necessary for managing TB in patients with HIV co-infection (drug interactions, IRIS), pregnancy, and hepatic or renal impairment.
• Adherence support, often through Directly Observed Therapy (DOT), and systematic clinical and laboratory monitoring are integral components of successful TB management.

6.1. Clinical Pearls

• Rifampicin is the most important drug for preventing relapse due to its potent sterilizing activity; its total duration in the regimen is critical.
• For asymptomatic transaminase elevation <5x ULN, therapy can often continue with close monitoring. Stop all potentially hepatotoxic drugs if symptoms develop or if transaminases are ≥5x ULN.
• Always administer pyridoxine (25–50 mg daily) with isoniazid to prevent peripheral neuropathy, especially in high-risk patients (pregnant women, elderly, malnourished, HIV-positive, diabetic).
• In patients on rifampicin, advise that urine, sweat, and tears may turn orange and that soft contact lenses may be permanently stained.
• When treating MDR-TB, a baseline ECG is essential before starting bedaquiline or fluoroquinolones, and electrolytes (potassium, magnesium, calcium) should be monitored and corrected to minimize QT prolongation risk.

References

1. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
5. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.